Global Dengue Vaccines Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global Dengue Vaccines market size will reach 643.42 Million USD in 2025 and is projected to reach 1,479.36 Million USD by 2032, with a CAGR of 12.63% (2025-2032). Notably, the China Dengue Vaccines market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Dengue vaccines are immunizations developed to protect against dengue fever, a viral disease transmitted through the bites of infected mosquitoes, primarily Aedes aegypti and Aedes albopictus. The vaccines are designed to stimulate the immune system to produce antibodies against the dengue virus, preventing or reducing the severity of the infection if a vaccinated person is exposed to the virus. Several dengue vaccines have been developed, including the CYD-TDV vaccine (Dengvaxia), which has been approved for use in some countries. Dengue vaccines are particularly important in regions where dengue is endemic and poses a significant public health threat. However, developing an effective dengue vaccine has been challenging due to the existence of multiple dengue virus serotypes, which require the vaccine to provide protection against all four serotypes. Continued research and efforts are focused on improving dengue vaccines to enhance their safety and efficacy, contributing to global efforts to control and prevent the spread of dengue fever.
The major global suppliers of Dengue Vaccines include Sanofi, Takeda, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Dengue Vaccines. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Dengue Vaccines market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Dengue Vaccines market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Dengue Vaccines industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Dengue Vaccines Include:
Sanofi
Takeda
Dengue Vaccines Product Segment Include:
Dengvaxia
TAK-003
Others
Dengue Vaccines Product Application Include:
Preventive Vaccination in Endemic Regions
Protection for Travelers
Integration into Routine Immunization Programs
Occupational Vaccination
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Dengue Vaccines Industry PESTEL Analysis
Chapter 3: Global Dengue Vaccines Industry Porter's Five Forces Analysis
Chapter 4: Global Dengue Vaccines Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Dengue Vaccines Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Dengue Vaccines Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Dengue Vaccines Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global Dengue Vaccines market size will reach 643.42 Million USD in 2025 and is projected to reach 1,479.36 Million USD by 2032, with a CAGR of 12.63% (2025-2032). Notably, the China Dengue Vaccines market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Dengue vaccines are immunizations developed to protect against dengue fever, a viral disease transmitted through the bites of infected mosquitoes, primarily Aedes aegypti and Aedes albopictus. The vaccines are designed to stimulate the immune system to produce antibodies against the dengue virus, preventing or reducing the severity of the infection if a vaccinated person is exposed to the virus. Several dengue vaccines have been developed, including the CYD-TDV vaccine (Dengvaxia), which has been approved for use in some countries. Dengue vaccines are particularly important in regions where dengue is endemic and poses a significant public health threat. However, developing an effective dengue vaccine has been challenging due to the existence of multiple dengue virus serotypes, which require the vaccine to provide protection against all four serotypes. Continued research and efforts are focused on improving dengue vaccines to enhance their safety and efficacy, contributing to global efforts to control and prevent the spread of dengue fever.
The major global suppliers of Dengue Vaccines include Sanofi, Takeda, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Dengue Vaccines. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Dengue Vaccines market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Dengue Vaccines market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Dengue Vaccines industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Dengue Vaccines Include:
Sanofi
Takeda
Dengue Vaccines Product Segment Include:
Dengvaxia
TAK-003
Others
Dengue Vaccines Product Application Include:
Preventive Vaccination in Endemic Regions
Protection for Travelers
Integration into Routine Immunization Programs
Occupational Vaccination
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Dengue Vaccines Industry PESTEL Analysis
Chapter 3: Global Dengue Vaccines Industry Porter's Five Forces Analysis
Chapter 4: Global Dengue Vaccines Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Dengue Vaccines Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Dengue Vaccines Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Dengue Vaccines Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Dengue Vaccines Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Dengue Vaccines Product by Type
- 1.2.1 Dengvaxia
- 1.2.2 TAK-003
- 1.2.3 Others
- 1.3 Dengue Vaccines Product by Application
- 1.3.1 Preventive Vaccination in Endemic Regions
- 1.3.2 Protection for Travelers
- 1.3.3 Integration into Routine Immunization Programs
- 1.3.4 Occupational Vaccination
- 1.4 Global Dengue Vaccines Market Size Analysis (2020-2032)
- 1.5 Dengue Vaccines Market Development Status and Trends
- 1.5.1 Dengue Vaccines Industry Development Status Analysis
- 1.5.2 Dengue Vaccines Industry Development Trends Analysis
- 2 Dengue Vaccines Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Dengue Vaccines Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Dengue Vaccines Market Analysis by Country
- 4.1 Global Dengue Vaccines Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Dengue Vaccines Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Dengue Vaccines Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.5 China Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.6 France Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.14 India Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Dengue Vaccines Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Dengue Vaccines Market Revenue by Key Suppliers (2021-2025)
- 5.2 Dengue Vaccines Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Dengue Vaccines Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Dengue Vaccines Market Analysis by Type
- 6.1 Global Dengue Vaccines Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Dengue Vaccines Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Sanofi
- 7.1.1 Sanofi Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Sanofi Dengue Vaccines Product Portfolio
- 7.1.3 Sanofi Dengue Vaccines Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Takeda
- 7.2.1 Takeda Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Takeda Dengue Vaccines Product Portfolio
- 7.2.3 Takeda Dengue Vaccines Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 Dengue Vaccines Industry Chain Analysis
- 8.2 Dengue Vaccines Product Downstream Application Analysis
- 8.2.1 Global Dengue Vaccines Market Size and Growth Rate (CAGR) by Application: 2024 VS 2025 VS 2032
- 8.2.2 Global Dengue Vaccines Revenue and Forecast by Application (2020-2032)
- 8.3 Dengue Vaccines Typical Downstream Customers
- 8.4 Dengue Vaccines Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
